Commentary|Articles|August 5, 2026

NeuroVoices: Brian Callaghan, MD, on Recapping the 2026 Peripheral Nerve Society Annual Meeting

Author(s)Marco Meglio, Brian Callaghan, MD, MS

The associate professor at the University of Michigan covered the 2026 Peripheral Nerve Society Annual Meeting, highlighting emerging themes in GBS, SMA, TTR neuropathy, RFC1, and what is still keeping the field up at night.

The 2026 Peripheral Nerve Society (PNS) Annual Meeting, held June 13 to 16 in Maastricht, Netherlands, brought together leading voices in peripheral nerve disease to discuss the latest research, debate unresolved questions, and preview what is coming next across conditions ranging from CIDP and GBS to hereditary neuropathies and TTR amyloidosis. From real-world treatment data to the early stages of CRISPR-based therapies, the meeting reflected a field in the middle of meaningful transformation.

Related to this article

November 4th, 2026

Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

November 4th, 2026

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

October 30th, 2026

Understanding Advances Shaping Precision Medicine for Generalized Myasthenia Gravis

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

October 28th, 2026

NeuroVoices: Bruce Ovbiagele, MD, MSc, MAS, MBA, on the Future of Stroke Publishing

The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.

October 27th, 2026

Collective Advocacy, Shared Priorities, and What’s Ahead at MDA 2027

Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.

November 6th, 2026

NeurologyLive® Friday 5 — November 6, 2026

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.

November 5th, 2026

Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy

Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.

November 5th, 2026

QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS

QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.